FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220777714> ?p ?o ?g. }

• W4220777714 abstract "Abstract The all-oral combination of ixazomib, cyclophosphamide, and dexamethasone (ICD) is well tolerated and effective in newly diagnosed and relapsed multiple myeloma (MM). We carried out MUKeight, a randomised, controlled, open, parallel group, multi-centre phase II trial in patients with relapsed MM after prior treatment with thalidomide, lenalidomide, and a proteasome inhibitor (ISRCTN58227268), with the primary objective to test whether ICD has improved clinical activity compared to cyclophosphamide and dexamethasone (CD) in terms of progression-free survival (PFS). Between January 2016 and December 2018, 112 participants were randomised between ICD ( n = 58) and CD ( n = 54) in 33 UK centres. Patients had a median age of 70 years and had received a median of four prior lines of therapy. 74% were classed as frail. Median PFS in the ICD arm was 5.6 months, compared to 6.7 months with CD (hazard ratio (HR) = 1.21, 80% CI 0.9–1.6, p = 0.3634). Response rates and overall survival were not significantly different between ICD and CD. Dose modifications or omissions, and serious adverse events (SAEs), occurred more often in the ICD arm. In summary, the addition of ixazomib to cyclophosphamide and dexamethasone did not improve outcomes in the comparatively frail patients enroled in the MUKeight trial." @default.
• W4220777714 created "2022-04-03" @default.
• W4220777714 creator A5001499861 @default.
• W4220777714 creator A5016246851 @default.
• W4220777714 creator A5033896752 @default.
• W4220777714 creator A5038580329 @default.
• W4220777714 creator A5049587707 @default.
• W4220777714 creator A5060242205 @default.
• W4220777714 creator A5063649925 @default.
• W4220777714 creator A5071715167 @default.
• W4220777714 creator A5073477610 @default.
• W4220777714 creator A5073685514 @default.
• W4220777714 creator A5079368352 @default.
• W4220777714 creator A5086640521 @default.
• W4220777714 date "2022-04-01" @default.
• W4220777714 modified "2023-10-17" @default.
• W4220777714 title "Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results" @default.
• W4220777714 cites W1973888964 @default.
• W4220777714 cites W1980168719 @default.
• W4220777714 cites W2013370486 @default.
• W4220777714 cites W2044436186 @default.
• W4220777714 cites W2071645392 @default.
• W4220777714 cites W2123159083 @default.
• W4220777714 cites W2124560610 @default.
• W4220777714 cites W2157105776 @default.
• W4220777714 cites W2319764074 @default.
• W4220777714 cites W2343386476 @default.
• W4220777714 cites W2403983357 @default.
• W4220777714 cites W2525525075 @default.
• W4220777714 cites W2622796688 @default.
• W4220777714 cites W2776494374 @default.
• W4220777714 cites W2884753909 @default.
• W4220777714 cites W2901300056 @default.
• W4220777714 cites W2901369628 @default.
• W4220777714 cites W2901427490 @default.
• W4220777714 cites W2912018514 @default.
• W4220777714 cites W2919022600 @default.
• W4220777714 cites W2943565624 @default.
• W4220777714 cites W2969287051 @default.
• W4220777714 cites W2975797573 @default.
• W4220777714 cites W2997240421 @default.
• W4220777714 cites W3005849948 @default.
• W4220777714 cites W3008991061 @default.
• W4220777714 cites W3036660876 @default.
• W4220777714 cites W3091650880 @default.
• W4220777714 cites W3105812043 @default.
• W4220777714 cites W3127065235 @default.
• W4220777714 cites W3132078350 @default.
• W4220777714 cites W3133701599 @default.
• W4220777714 cites W3134103265 @default.
• W4220777714 cites W3136388199 @default.
• W4220777714 cites W3137319952 @default.
• W4220777714 cites W3158532759 @default.
• W4220777714 cites W3200986146 @default.
• W4220777714 cites W4211191410 @default.
• W4220777714 cites W4232326942 @default.
• W4220777714 doi "https://doi.org/10.1038/s41408-022-00626-4" @default.
• W4220777714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35365598" @default.
• W4220777714 hasPublicationYear "2022" @default.
• W4220777714 type Work @default.
• W4220777714 citedByCount "7" @default.
• W4220777714 countsByYear W42207777142022 @default.
• W4220777714 countsByYear W42207777142023 @default.
• W4220777714 crossrefType "journal-article" @default.
• W4220777714 hasAuthorship W4220777714A5001499861 @default.
• W4220777714 hasAuthorship W4220777714A5016246851 @default.
• W4220777714 hasAuthorship W4220777714A5033896752 @default.
• W4220777714 hasAuthorship W4220777714A5038580329 @default.
• W4220777714 hasAuthorship W4220777714A5049587707 @default.
• W4220777714 hasAuthorship W4220777714A5060242205 @default.
• W4220777714 hasAuthorship W4220777714A5063649925 @default.
• W4220777714 hasAuthorship W4220777714A5071715167 @default.
• W4220777714 hasAuthorship W4220777714A5073477610 @default.
• W4220777714 hasAuthorship W4220777714A5073685514 @default.
• W4220777714 hasAuthorship W4220777714A5079368352 @default.
• W4220777714 hasAuthorship W4220777714A5086640521 @default.
• W4220777714 hasBestOaLocation W42207777141 @default.
• W4220777714 hasConcept C126322002 @default.
• W4220777714 hasConcept C141071460 @default.
• W4220777714 hasConcept C143998085 @default.
• W4220777714 hasConcept C197934379 @default.
• W4220777714 hasConcept C207103383 @default.
• W4220777714 hasConcept C2776063141 @default.
• W4220777714 hasConcept C2776364478 @default.
• W4220777714 hasConcept C2776694085 @default.
• W4220777714 hasConcept C2776755627 @default.
• W4220777714 hasConcept C2779609412 @default.
• W4220777714 hasConcept C2780108899 @default.
• W4220777714 hasConcept C2780401358 @default.
• W4220777714 hasConcept C2780739268 @default.
• W4220777714 hasConcept C2781098529 @default.
• W4220777714 hasConcept C44249647 @default.
• W4220777714 hasConcept C71924100 @default.
• W4220777714 hasConceptScore W4220777714C126322002 @default.
• W4220777714 hasConceptScore W4220777714C141071460 @default.
• W4220777714 hasConceptScore W4220777714C143998085 @default.
• W4220777714 hasConceptScore W4220777714C197934379 @default.
• W4220777714 hasConceptScore W4220777714C207103383 @default.
• W4220777714 hasConceptScore W4220777714C2776063141 @default.
• W4220777714 hasConceptScore W4220777714C2776364478 @default.

• next